Immunology Research
To learn more about immune system conditions and ongoing clinical trials in this area, visit our Immunology Research page.
Learn MoreThe main purpose of the study is to assess efficacy and safety of Baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
Have severe areata alopecia (AA) for at least 1 year
Current AA episode of at least 6 months’ duration with hair loss encompassing ≥50% of the scalp
Current episode of severe to very severe alopecia areata of less than 8 years
Participants who have severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years
Participants must not have primarily “diffuse” type of alopecia areata
Participants must not be currently experiencing other forms of alopecia or any other health problem that would make it difficult to see how the study drug is working on alopecia areata
Participants must not have topical applied to scalp within 4 weeks of randomization
To learn more about immune system conditions and ongoing clinical trials in this area, visit our Immunology Research page.
Learn MoreTo learn more about pediatric clinical trials, and access resources for children, young people, and caregivers, visit our Pediatric Research page.
Learn MoreA clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.